Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Daijiro Harada"'
Autor:
Tomoki, Tamura, Kiichiro, Ninomiya, Toshio, Kubo, Shoichi, Kuyama, Sayaka, Tachibana, Koji, Inoue, Kenichi, Chikamori, Kenichiro, Kudo, Nobuaki, Ochi, Daijiro, Harada, Yoshinobu, Maeda, Katsuyuki, Kiura
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 453-459 (2022)
Thoracic Cancer
Thoracic Cancer
Background Since 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become prevalent worldwide. In severe cases, the case fatality rate is high, and vaccine prevention is important. This study evaluated the safety of receiving
Autor:
Keisuke Aoe, Shoichi Kuyama, Koji Inoue, Kazuhiro Yatera, Takayuki Suetsugu, Minoru Fukuda, Nobukazu Fujimoto, Kosuke Kashiwabara, Noriyuki Ebi, Fumihiro Tanaka, Daijiro Harada, Akihiro Nishiyama, Chiharu Yoshii, Hitomi Umeguchi, Hironori Yoshida, Atsushi Kawaguchi, Chiho Nakashima, Katsumi Nakatomi, Kentaro Iwanaga, Ayako Takamori, Genju Koh, Naoko Sueoka-Aragane, Nobuhiko Seki, Hidetaka Uramoto, Naohisa Matsumoto, Sunao Ushijima, Kaname Nosaki
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Cancer Medicine
Cancer Medicine
Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic
Autor:
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 643-649 (2021)
Thoracic Cancer
Thoracic Cancer
Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal ep
Autor:
Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares, Nataliia Voitko, Andrzej Kazarnowicz, Mustafa Özgüroglu, Nikolay Conev, Maximilian Hochmair, Otto Burghuber, Irfan Çiçin, Vladimir Moiseenko, Mustafa Erman, Dariusz Kowalski, Marek Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Maria Amelia Insa Molla, Grygorii Ursol, Anne Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Sang-We Kim, Alexey Smolin, Tuncay Göksel, Shaker Dakhil, Jaromir Roubec, Krisztina Bogos, Robin Cornelissen, Jong-Seok Lee, Maria Rosario Garcia Campelo, Marta Lopez Brea, Ahmet Alacacioglu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, Attila Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong-Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, Margarita Majem Tarruella, David Spigel, Krassimir Koynov, Milada Zemanova, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Cecilia Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Slawomir Mandziuk, Yun Gyoo Lee, Lyubov Vladimirova, Dolores Isla Casado, Manuel Domine Gomez, Alejandro Navarro Mendivil, Teresa Morán Bueno, Shang-Yin Wu, Jeanna Knoble, Jana Skrickova, Violetka Venkova, Werner Hilgers, Eckart Laack, Helge Bischoff, Andrea Fülöp, Ibolya Laczó, Judit Kósa, András Telekes, Tatsuya Yoshida, Shintaro Kanda, Toyoaki Hida, Hidetoshi Hayashi, Tadashi Maeda, Tetsuji Kawamura, Yasuharu Nakahara, Niels Claessens, Ki Hyeong Lee, Chao-Hua Chiu, Sheng-Hao Lin, Chien-Te Li, Ahmet Demirkazik, Eric Schaefer, Petros Nikolinakos, Jeffrey Schneider, Sunil Babu, Bernd Lamprecht, Michael Studnicka, Carlos Fausto Nino Gorini, Juraj Kultan, Vitezslav Kolek, Pierre-Jean Souquet, Denis Moro-Sibilot, Maya Gottfried, Egbert Smit, Kyung Hee Lee, Peter Kasan, Jozef Chovanec, Olexandr Goloborodko, Oleksii Kolesnik, Yuriy Ostapenko, Shailendra Lakhanpal, Basir Haque, Winston Chua, Joseph Stilwill, Susana Noemi Sena, Gustavo Colagiovanni Girotto, Pedro Rafael Martins De Marchi, Fabricio Augusto Martinelli de Oliveira, Pedro Dos Reis, Rositsa Krasteva, Yanqiu Zhao, Chengshui Chen, Leona Koubkova, Gilles Robinet, Christos Chouaid, Christian Grohe, Jürgen Alt, Eszter Csánky, Éva Somogyiné Ezer, Norman Isaac Heching, Young Hak Kim, Shinji Aatagi, Shoichi Kuyama, Daijiro Harada, Naoyuki Nogami, Hiroshi Nokihara, Hisatsugu Goto, Agnes Staal van den Brekel, Eun Kyung Cho, Joo-Hang Kim, Doina Ganea, Tudor Ciuleanu, Ekaterina Popova, Dina Sakaeva, Marian Stresko, Pavol Demo, Robert Godal, Yu-Feng Wei, Yen-Hsun Chen, Te-Chun Hsia, Kang-Yun Lee, Huang-Chih Chang, Chin-Chou Wang, Afshin Dowlati, Christopher Sumey, Steven Powell, Jonathan Goldman, Juan Jose Zarba, Emilio Batagelj, Andrea Viviana Pastor, Mauro Zukin, Clarissa Serodio da Rocha Baldotto, Luis Alberto Schlittler, Aknar Calabrich, Claudia Sette, Asen Dudov, Caicun Zhou, Hervé Lena, Susanne Lang, Zsuzsanna Pápai, Koichi Goto, Shigeki Umemura, Kenya Kanazawa, Yu Hara, Masahiro Shinoda, Masahiro Morise, Jeroen Hiltermann, Robert Mróz, Andrei Ungureanu, Igor Andrasina, Gee-Chen Chang, Ihor Vynnychenko, Yaroslav Shparyk, Anna Kryzhanivska, Helen Ross, Kailhong Mi, Rodney Jamil, Michael Williamson, Joseph Spahr, Zhigang Han, Mengzhao Wang, Zhixiong Yang, Jie Hu, Wei Li, Jun Zhao, Jifeng Feng, Shenglin Ma, Xiangdong Zhou, Zongan Liang, Yi Hu, Yuan Chen, Minghong Bi, Yongqian Shu, Kejun Nan, Jianying Zhou, Wei Zhang, Rui Ma, Nong Yang, Zhong Lin, Gang Wu, Jian Fang, Helong Zhang, Kai Wang, Zhendong Chen
Publikováno v:
The Lancet Oncology, 22(1), 51-65. Lancet Publishing Group
Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive-stage small-cell lung cance
Autor:
Kazuhiko Yamada, Yoichi Nakamura, Sakiko Otani, Kazuma Kishi, Takeharu Yamanaka, Hiroshi Tanaka, Haruhiro Saito, Kaoru Kubota, Tsuneo Shimokawa, Yuichi Takiguchi, Hiroaki Okamoto, Toshihiro Misumi, Terufumi Kato, Yukio Hosomi, Daijiro Harada, Takashi Kasai
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cisplatin‐based chemoradiotherapy is considered standard treatment for unresectable locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with
Autor:
Daisuke Minami, Hiromi Watanabe, Katsuyuki Hotta, Masahiro Tabata, Kenichiro Kudo, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Etsuko Murakami, Kammei Rai, Nobuaki Ochi, Kiichiro Ninomiya, Katsuyuki Kiura, Kadoaki Ohashi, Daijiro Harada, Yoshinobu Maeda, Masayuki Yasugi, Keiichi Fujiwara
Publikováno v:
Japanese Journal of Clinical Oncology. 50:1447-1453
Objectives Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged
Autor:
Naoyuki Nogami, Shunta Mori, Yumi Asakura, Daijiro Harada, Kenji Takata, Takayuki Ohno, Satoko Moriki, Toshiyuki Kozuki, Yoshika Takechi
Publikováno v:
Anticancer Research. 39:4987-4993
Background/aim For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. Patients and methods From June 2013 to July 2018
Autor:
Katsuyuki Kiura, Takuya Fukazawa, Daijiro Harada, Masami Takeyama, Hiromichi Yamane, Tomoko Ikeda, Noriko Miyake, Nobuaki Ochi, Nagio Takigawa, Nozomu Nakagawa, Etsuko Yokota, Hidekazu Nakanishi, Yasunari Nagasaki
Publikováno v:
Experimental cell research. 409(2)
Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) may be involved in overcoming EGFR-TKI
Autor:
Tsuyoshi, Ueno, Yuho, Maki, Ryujiro, Sugimoto, Hiroshi, Suehisa, Motohiro, Yamashita, Daijiro, Harada, Toshiyuki, Kozuki, Naoyuki, Nogami
Publikováno v:
Acta Medica Okayama. 73(4):325-331
Therapeutic approaches to bronchopleural fistula (BPF) closure after lung resection are surgical or endoscopic interventions. We evaluated therapeutic outcomes to determine the optimal approach. We reviewed 15 patients who had developed BPF after lun
Autor:
Naoyuki Nogami, Toshio Kubo, Kadoaki Ohashi, Nobuaki Fukamatsu, Katsuyuki Kiura, Toshiyuki Kozuki, Daijiro Harada, Akihiro Bessho, Shinobu Hosokawa, Masayuki Yasugi, Hiroshige Yoshioka, Katsuyuki Hotta, Toshihide Yokoyama, Shoichi Kuyama, Isao Oze, Nagio Takigawa, Kenichiro Kudo, Naoyuki Sone
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation